CARLSBAD, Calif., Sept. 3, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the following investor conferences:
- 10th Annual Wells Fargo Healthcare Conference on
Thursday, September 10, 2015 in
Boston, MA;
- 2015 Morgan Stanley Global Healthcare Conference on
Friday, September 18, 2015 in
New York, NY; and
- Leerink Partners Rare Disease Roundtable on Wednesday, September 30, 2015 in New York, NY.
The above listed dates are subject to change. Details on
presentation times or changes to presentation dates can be found on
the Company's website. Please check www.isispharm.com for the
latest information.
A live webcast of the presentations will be available on the
"Investors & Media" section of the Isis website. The replays
will be available within 48 hours and will be archived for a
limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting
its leadership position in RNA-targeted technology to discover and
develop novel drugs for its product pipeline and for its partners.
Isis' broad pipeline consists of 38 drugs to treat a wide variety
of diseases with an emphasis on cardiovascular, metabolic, severe
and rare diseases, including neurological disorders, and cancer.
Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO®, in the United
States and other countries for the treatment of patients
with homozygous FH. Isis has numerous drugs in Phase 3 development
in severe/rare diseases and cardiovascular diseases. These include
volanesorsen, a drug Isis is developing and plans to commercialize
through its wholly owned subsidiary, Akcea Therapeutics, to treat
patients with familial chylomicronemia syndrome and familial
partial lipodystrophy; ISIS-TTRRx, a drug Isis is
developing with GSK to treat patients with the polyneuropathy and
cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNRx,
a drug Isis is developing with Biogen to treat infants and children
with spinal muscular atrophy, a severe and rare neuromuscular
disease. Isis' patents provide strong and extensive protection for
its drugs and technology. Additional information about Isis is
available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This
press release includes forward-looking statements regarding Isis
Pharmaceuticals' financial position and outlook, Isis' business,
and the therapeutic and commercial potential of Isis' technologies
and products, including KYNAMRO, volanesorsen,
ISIS-SMNRx and ISIS-TTRRx, in development.
Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking
statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Isis' forward-looking statements also
involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements. Although
Isis' forward-looking statements reflect the good faith judgment of
its management, these statements are based only on facts and
factors currently known by Isis. As a result, you are cautioned not
to rely on these forward-looking statements. These and other risks
concerning Isis' programs are described in additional detail in
Isis' annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of
these and other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of
Isis Pharmaceuticals, Inc. KYNAMRO® is a registered
trademark of Genzyme Corporation.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300137302.html
SOURCE Isis Pharmaceuticals, Inc.